BioCentury | Oct 20, 2014
Company News

Angiotech management update

Angiotech Pharmaceuticals Inc. , Vancouver, B.C. Business: Autoimmune, Cardiovascular, Dermatology Hired: John Barr as CEO, formerly EVP and president of global surgical at Bausch + Lomb Inc. , which Valeant Pharmaceuticals International Inc. acquired WIR Staff autoimmune...
BioCentury | May 5, 2014
Clinical News

MultiStem: Interim Phase II data

...UC (see BioCentury, Jan. 4, 2010). In 2011, Athersys regained all rights to MultiStem from Angiotech Pharmaceuticals Inc....
BioCentury | Dec 23, 2013
Clinical News

MultiStem: Completed Phase II enrollment

...UC (see BioCentury, Jan. 4, 2010). In 2011, Athersys regained all rights to MultiStem from Angiotech Pharmaceuticals Inc....
BioCentury | Oct 21, 2013
Company News

Angiotech management update

Angiotech Pharmaceuticals Inc. , Vancouver, B.C. Business: Autoimmune, Cardiovascular, Dermatology Transitioned: Thomas Bailey to a director from president and CEO; and Victor Diaz to president and COO from EVP of global manufacturing and supply chain management...
BioCentury | Apr 22, 2013
Company News

Angiotech, Argon Medical Devices Inc. deal

...Argon Medical Devices Inc. (Athens, Texas) completed the acquisition of Angiotech's Interventional Products Business for $362.5...
...company of private equity firm RoundTable Healthcare Partners (Lake Forest, Ill.) (see BioCentury, April 1). Angiotech Pharmaceuticals Inc....
BioCentury | Apr 8, 2013
Financial News

Angiotech financial update

...accrued and unpaid interest. Following the repurchase, $44 million of the notes will remain outstanding. Angiotech Pharmaceuticals Inc....
BioCentury | Apr 1, 2013
Company News

Angiotech, RoundTable Healthcare Partners deal

...Medical Devices Inc. (Athens, Texas), a portfolio company of private equity firm RoundTable, will acquire Angiotech's...
...Fla.; and Rochester, N.Y. The deal is slated to close by the end of April. Angiotech...
...created in 2003 through an investment from RoundTable Healthcare Partners (see BioCentury, March 27, 2006). Angiotech Pharmaceuticals Inc....
BioCentury | Dec 3, 2012
Clinical News

Zilver PTX Drug-Eluting Stent regulatory update

...Cook licensed rights to use paclitaxel in stents from Angiotech (see BioCentury, July 14, 1997). Angiotech Pharmaceuticals Inc....
BioCentury | Oct 15, 2012
Clinical News

Athersys preclinical data

...IBD (see BioCentury, Jan. 4, 2010). Last year, Athersys regained all rights to MultiStem from Angiotech Pharmaceuticals Inc....
BioCentury | Oct 8, 2012
Clinical News

MultiStem: Phase II ongoing

...IBD (see BioCentury, Jan. 4, 2010). Last year, Athersys regained all rights to MultiStem from Angiotech Pharmaceuticals Inc....
Items per page:
1 - 10 of 514
BioCentury | Oct 20, 2014
Company News

Angiotech management update

Angiotech Pharmaceuticals Inc. , Vancouver, B.C. Business: Autoimmune, Cardiovascular, Dermatology Hired: John Barr as CEO, formerly EVP and president of global surgical at Bausch + Lomb Inc. , which Valeant Pharmaceuticals International Inc. acquired WIR Staff autoimmune...
BioCentury | May 5, 2014
Clinical News

MultiStem: Interim Phase II data

...UC (see BioCentury, Jan. 4, 2010). In 2011, Athersys regained all rights to MultiStem from Angiotech Pharmaceuticals Inc....
BioCentury | Dec 23, 2013
Clinical News

MultiStem: Completed Phase II enrollment

...UC (see BioCentury, Jan. 4, 2010). In 2011, Athersys regained all rights to MultiStem from Angiotech Pharmaceuticals Inc....
BioCentury | Oct 21, 2013
Company News

Angiotech management update

Angiotech Pharmaceuticals Inc. , Vancouver, B.C. Business: Autoimmune, Cardiovascular, Dermatology Transitioned: Thomas Bailey to a director from president and CEO; and Victor Diaz to president and COO from EVP of global manufacturing and supply chain management...
BioCentury | Apr 22, 2013
Company News

Angiotech, Argon Medical Devices Inc. deal

...Argon Medical Devices Inc. (Athens, Texas) completed the acquisition of Angiotech's Interventional Products Business for $362.5...
...company of private equity firm RoundTable Healthcare Partners (Lake Forest, Ill.) (see BioCentury, April 1). Angiotech Pharmaceuticals Inc....
BioCentury | Apr 8, 2013
Financial News

Angiotech financial update

...accrued and unpaid interest. Following the repurchase, $44 million of the notes will remain outstanding. Angiotech Pharmaceuticals Inc....
BioCentury | Apr 1, 2013
Company News

Angiotech, RoundTable Healthcare Partners deal

...Medical Devices Inc. (Athens, Texas), a portfolio company of private equity firm RoundTable, will acquire Angiotech's...
...Fla.; and Rochester, N.Y. The deal is slated to close by the end of April. Angiotech...
...created in 2003 through an investment from RoundTable Healthcare Partners (see BioCentury, March 27, 2006). Angiotech Pharmaceuticals Inc....
BioCentury | Dec 3, 2012
Clinical News

Zilver PTX Drug-Eluting Stent regulatory update

...Cook licensed rights to use paclitaxel in stents from Angiotech (see BioCentury, July 14, 1997). Angiotech Pharmaceuticals Inc....
BioCentury | Oct 15, 2012
Clinical News

Athersys preclinical data

...IBD (see BioCentury, Jan. 4, 2010). Last year, Athersys regained all rights to MultiStem from Angiotech Pharmaceuticals Inc....
BioCentury | Oct 8, 2012
Clinical News

MultiStem: Phase II ongoing

...IBD (see BioCentury, Jan. 4, 2010). Last year, Athersys regained all rights to MultiStem from Angiotech Pharmaceuticals Inc....
Items per page:
1 - 10 of 514